Nadler Financial Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.94M Buy
7,729
+198
+3% +$42.6K 0.16% 44
2026
Q1
$1.64M Sell
7,531
-896
-11% -$199K 0.16% 46
2025
Q4
$1.93M Sell
8,427
-252
-3% -$57.4K 0.18% 44
2025
Q3
$2.01M Sell
8,679
-205
-2% -$41.7K 0.19% 40
2025
Q2
$1.65M Sell
8,884
-586
-6% -$109K 0.17% 44
2025
Q1
$1.98M Sell
9,470
-109
-1% -$21.2K 0.22% 41
2024
Q4
$1.7M Sell
9,579
-10
-0.1% -$1.84K 0.18% 41
2024
Q3
$1.89M Sell
9,589
-30
-0.3% -$5.6K 0.21% 41
2024
Q2
$1.65M Sell
9,619
-161
-2% -$26.7K 0.19% 41
2024
Q1
$1.78M Sell
9,780
-36
-0.4% -$6.2K 0.22% 39
2023
Q4
$1.52M Sell
9,816
-4,107
-29% -$599K 0.2% 38
2023
Q3
$2.08M Sell
13,923
-87
-0.6% -$12.8K 0.31% 34
2023
Q2
$1.89M Sell
14,010
-1,183
-8% -$173K 0.28% 35
2023
Q1
$2.42M Buy
15,193
+7
+0% +$1.07K 0.39% 31
2022
Q4
$2.45M Sell
15,186
-793
-5% -$122K 0.43% 29
2022
Q3
$2.15M Buy
15,979
+76
+0.5% +$10.9K 0.41% 31
2022
Q2
$2.44M Buy
15,903
+52
+0.3% +$7.95K 0.45% 30
2022
Q1
$2.57M Sell
15,851
-1,196
-7% -$174K 0.4% 30
2021
Q4
$2.31M Buy
17,047
+319
+2% +$37.7K 0.34% 34
2021
Q3
$1.8M Buy
16,728
+837
+5% +$95.6K 0.29% 38
2021
Q2
$1.79M Buy
15,891
+405
+3% +$45.6K 0.29% 35
2021
Q1
$1.68M Buy
15,486
+413
+3% +$44.2K 0.3% 36
2020
Q4
$1.61M Sell
15,073
-1,940
-11% -$186K 0.31% 35
2020
Q3
$1.49M Sell
17,013
-112
-0.7% -$10.5K 0.33% 33
2020
Q2
$1.68M Buy
17,125
+2,180
+15% +$192K 0.42% 29
2020
Q1
$1.14M Sell
14,945
-256
-2% -$21.8K 0.35% 30
2019
Q4
$1.35M Buy
15,201
+5,628
+59% +$467K 0.33% 31
2019
Q3
$725K Sell
9,573
-5
-0.1% -$343 0.2% 41
2019
Q2
$697K Sell
9,578
-505
-5% -$39.7K 0.2% 42
2019
Q1
$813K Sell
10,083
-1,180
-10% -$96.5K 0.26% 39
2018
Q4
$1.04M Sell
11,263
-923
-8% -$81.2K 0.34% 29
2018
Q3
$1.15M Sell
12,186
-35
-0.3% -$3.32K 0.31% 32
2018
Q2
$1.13M Buy
12,221
+1,167
+11% +$114K 0.32% 32
2018
Q1
$1.05M Sell
11,054
-793
-7% -$87.1K 0.32% 30
2017
Q4
$1.15M Buy
11,847
+703
+6% +$66.3K 0.35% 30
2017
Q3
$990K Buy
11,144
+54
+0.5% +$4.11K 0.33% 31
2017
Q2
$804K Buy
11,090
+3
+0% +$202 0.27% 34
2017
Q1
$722K Sell
11,087
-267
-2% -$16.8K 0.25% 36
2016
Q4
$711K Buy
11,354
+182
+2% +$11.1K 0.26% 35
2016
Q3
$705K Buy
11,172
+1,369
+14% +$88.6K 0.28% 33
2016
Q2
$607K Buy
9,803
+3
+0% +$183 0.26% 37
2016
Q1
$560K Buy
9,800
+104
+1% +$5.8K 0.24% 39
2015
Q4
$574K Sell
9,696
-729
-7% -$42K 0.26% 37
2015
Q3
$567K Buy
10,425
+69
+0.7% +$4.49K 0.28% 36
2015
Q2
$696K Buy
10,356
+3,096
+43% +$202K 0.33% 33
2015
Q1
$425K Sell
7,260
-415
-5% -$25.1K 0.2% 45
2014
Q4
$502K Buy
7,675
+187
+2% +$11.8K 0.26% 42
2014
Q3
$433K Sell
7,488
-26
-0.3% -$1.44K 0.26% 40
2014
Q2
$424K Sell
7,514
-100
-1% -$5.25K 0.27% 37
2014
Q1
$391K Hold
7,614
0.26% 42
2013
Q4
$402K Hold
7,614
0.26% 43
2013
Q3
$341K Sell
7,614
-1,349
-15% -$59.8K 0.25% 48
2013
Q2
$371K Buy
+8,963
New +$392K 0.26% 46

Other funds holding ABBV

Nadler Financial Group's ABBV Position: Q2 2026 in Review

Nadler Financial Group increased its AbbVie (ABBV) stake by 2.6% in Q2 2026, buying an estimated $42.6K and bringing the position to 7,729 shares worth $1.94M. The position accounts for 0.16% of the portfolio, ranked #44.

Nadler Financial Group first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.57M in Q1 2022. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nadler Financial Group held 7,729 shares of AbbVie worth $1.94M as of Q2 2026.
  • Nadler Financial Group bought 198 AbbVie shares in Q2 2026, an estimated $42.6K.
  • AbbVie made up 0.16% of Nadler Financial Group's portfolio in Q2 2026, its #44 holding.
  • Nadler Financial Group first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Nadler Financial Group's AbbVie position peaked at $2.57M in Q1 2022.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nadler Financial Group's 13F filing for Q2 2026, filed 30 Jul 2026.